Dr. Ali Al-Ghamrawy, Chairman of the Egyptian Drug Authority, held a meeting with representatives of global pharmaceutical companies, as part of the Authority’s commitment to enhancing strategic partnerships with the industrial sector and supporting the stability of the Egyptian pharmaceutical market.
During the meeting, Dr. Al-Ghamrawy emphasized that the Authority gives great importance to strengthening direct communication channels with partners in the pharmaceutical market, stressing that market stability represents a national priority and a fundamental pillar in supporting the healthcare system.
He explained that the Authority adopts flexible regulatory policies aligned with international best practices, ensuring accelerated access to innovative products and increased market competitiveness, while maintaining the highest standards of quality and safety.
In the context of enhancing transparency and partnership, the EDA affirmed that continuous dialogue with global companies is a key pillar in achieving the national vision for developing the pharmaceutical sector, facilitating supply chain movement, and supporting the investment climate—ultimately contributing to the rapid availability of the latest treatments for citizens and strengthening the market’s ability to meet pharmaceutical needs efficiently and effectively.
Representatives of the global pharmaceutical companies expressed their appreciation for the efforts made by the Egyptian Drug Authority in supporting market stability and improving regulatory policies. They affirmed that the Authority’s collaborative approach reflects a deep understanding of the nature and needs of the industry. They praised the professionalism and responsiveness of the EDA, noting that this cooperation paves the way for increased investments and wider opportunities to provide the latest treatments to patients in Egypt.
From the EDA side, the meeting was attended by:
• Dr. Hossam Abdullah, Associate to the Chairman for Market Support and Monitoring & General Manager of General Administration of Market Access and Business Continuity
• Eng. Mahmoud Raslan, a Data Analyst from the ""DAF"" company.
From the companies’ side, attendees included:
• Dr. Mohamed Amin, Board Member and Head of Market Support Sector, AstraZeneca
• Mr. Mohamed Gamal, Board Member and Chief Financial Officer (CFO), AstraZeneca
• Dr. Ola Sadeq, Scientific Office Manager and Head of Registration, Sandoz Egypt
• Dr. Yasmine El-Hennawy, Head of Specialty Pharmaceuticals and Market Expansion, Sandoz Egypt
• Dr. Maisoon Abubakr, Head of Pricing, Sanofi
• Dr. Loaloa Omar, Head of Patient Solutions, Sanofi
• Dr. Amr Saif, Regional Manager, Pfizer for Egypt, Sudan, the Levant, and Iraq
• Dr. Yomna Kotb, Head of Policy and Communications for the Middle East and Africa, Pfizer
• Dr. Rana Kotb, Patient Support Programs Manager and Market Access Lead – Rare Diseases, Pfizer
• Dr. Ziad El-Ahwal, Head of Government Affairs, Health Policies, and Market Support, Roche
• Dr. Ahmed Khorshed, Patient Support Manager, Roche
• Dr. Moataz El-Hattab, Head of Markets Support, Roche
This meeting reflects the Egyptian Drug Authority’s ambitious vision to build an integrated pharmaceutical ecosystem that supports innovation, promotes investment, and ensures the efficient and prompt availability of the latest treatments for citizens, in line with the highest international standards. It also contributes to strengthening the competitiveness of the Egyptian market and reinforces Egypt’s position as a leading regional hub for the pharmaceutical industry—marking a strategic step toward sector sustainability and advanced therapeutic solutions that meet the needs of all stakeholders.